Global Rise In Eye Diseases Drives Growth Of Ranibizumab Market Is Supporting Development Across The Ranibizumab Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Forecasted Rise In Market Size Of The Ranibizumab Market During The Forecast Period?

The ranibizumab market size has experienced consistent expansion in recent years. It is projected to expand from $2.76 billion in 2025 to $2.87 billion in 2026, at a compound annual growth rate (CAGR) of 4.0%. The growth observed in the past period can be attributed to the increasing prevalence of age-related macular degeneration, the clinical validation of anti-VEGF therapy efficacy, a rising incidence of diabetic retinopathy, improvements in diagnostic imaging for retinal disorders, and early regulatory approvals for ranibizumab.

The ranibizumab market is projected for consistent expansion in the coming years, with its value expected to reach $3.31 billion by 2030, reflecting a compound annual growth rate (CAGR) of 3.6%. This anticipated growth during the forecast period is primarily attributed to a globally increasing aging population, the rising prevalence of diabetes worldwide, broader access to advanced ophthalmic care, the growing adoption of intravitreal injections, and ongoing enhancements in retinal disease screening programs. Furthermore, significant trends shaping this period include the increased acceptance of anti-VEGF therapies for retinal conditions, a growing preference for prefilled syringe formulations, an elevated demand for treating diabetic eye disorders, the expansion of ophthalmology specialty care centers, and a higher utilization of long-term maintenance therapy for chronic retinal conditions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16172&type=smp

Which Growth Drivers Are Expected To Support The Ranibizumab Market Forward?

The ranibizumab market is expected to experience growth driven by the rising incidence of eye diseases. These conditions encompass a spectrum of ailments affecting the eyes, which can lead to impaired vision and overall ocular health issues. The growing prevalence of eye diseases is linked to factors such as an aging global population, shifting lifestyle habits, and an increase in chronic conditions like diabetes. Ranibizumab is utilized in the treatment of conditions such as age-related macular degeneration and diabetic retinopathy, playing a role in reducing vision impairment given the increasing occurrence of eye diseases. For illustration, in August 2023, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, indicated that approximately 2.2 billion people worldwide experience either near or distance vision impairment. Thus, the escalating prevalence of eye diseases will propel the expansion of the ranibizumab market.

How Does Segment Analysis Break Down The Ranibizumab Market Structure?

The ranibizumab market covered in this report is segmented –

1) By Product: Single Use Prefilled Syringe, Single Use Glass Vial

2) By Application: Wet Age Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Myopic Choroidal Neovascularization (MCNV), Retinal Vein Occlusion (RVO)

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Single Use Prefilled Syringe: 0.3 Ml Syringe, 0.5 Ml Syringe, 1 Ml Syringe, Other Volume Variants

2) By Single Use Glass Vial: 0.5 Mg Or 0.05 Ml Vial, 1.0 Mg Or 0.1 Ml Vial, 2.0 Mg Or 0.2 Ml Vial, Other Volume Variants

What Trends Are Influencing The Future Of The Ranibizumab Market?

Leading companies in the ranibizumab market are concentrating on cost-effective treatments, specifically ranibizumab biosimilars, to manage and prevent vision impairment in individuals suffering from retinal conditions. A ranibizumab biosimilar is a biological medicine that is highly similar to the original ranibizumab but is marketed under a distinct brand name, offering a more economical alternative while maintaining similar efficacy and safety profiles. For instance, in April 2024, Formycon AG, a Germany-based biotechnology company, and Bioeq AG, a Switzerland-based biopharmaceutical company, disclosed the commercial introduction of FYB201, a biosimilar to Lucentis (Ranibizumab), in Canada and Switzerland. This launch occurred after receiving marketing approval from Health Canada under the brand name Ranopto and from Swissmedic under the brand name Ranivisio. FYB201 provides a novel, high-quality, effective, and affordable treatment choice for patients affected by severe retinal diseases. It has already demonstrated its value as an economical treatment option for patients in the USA and various regions of Europe.

Which Organizations Are Involved In The Ranibizumab Market?

Major companies operating in the ranibizumab market are F. Hoffmann-La Roche AG, Genentech Inc., Bayer AG, Novartis AG, Biocon Limited, Samsung Biologics Co Ltd, Celltrion Healthcare Co Ltd, Formycon AG, Coherus BioSciences Inc, Xbrane Biopharma AB, Alvotech, Stada Arzneimittel AG, Sun Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories Ltd, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Intas Pharmaceuticals Ltd, Enzene Biosciences Ltd, Amman Pharmaceutical Industries

Access The Complete Ranibizumab Market Report:

https://www.thebusinessresearchcompany.com/report/ranibizumab-global-market-report

Which Region Contributes The Most To The Ranibizumab Market?

North America was the largest region in the ranibizumab market in 2025. The regions covered in the ranibizumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Ranibizumab Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=16172&type=smp

Browse Through More Reports Similar to the Global Ranibizumab Market 2026, By The Business Research Company

Ranibizumab Market Report 2026

https://www.thebusinessresearchcompany.com/report/ranibizumab-global-market-report

Ibrutinib Market Report 2026

https://www.thebusinessresearchcompany.com/report/ibrutinib-global-market-report

Takaful Market Report 2026

https://www.thebusinessresearchcompany.com/report/takaful-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795